02-May-2022

Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

Kazia CEO Dr James Garner tells Andrew Scott about the company's quarterly achievements, including data the company presented at the American Association of Cancer Research (AACR) conference on the use of its asset paxalisib in a rare, aggressive childhood cancer. It has been a busy quarter for the company on the trials front, and news for investors is good too, with the company introducing an at-the-market financing facility in the US - a quick and efficient way of transacting on biotech shares.

30-Apr-2022

Kazia to present final data from paxalisib phase II study as ASCO

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO).

28-Feb-2022

Kazia Therapeutics recruits first keto patient to Phase II paxalisib study for treatment of glioblastoma

Kazia Therapeutics (ASX: KZA)has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma.

14-Feb-2022

Kazia Therapeutics advances human trials for lead cancer drugs during December quarter

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December.

07-Feb-2022

Kazia Therapeutics To Present At BIO CEO Conference

Kazia Therapeutics Limited will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Kazia will be presenting in person on day one of the conference, Monday, 14 February. The presentation will provide an update on recent progress with Kazia's two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022

14-Dec-2021

Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer

In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022.

04-Dec-2021

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma.

02-Dec-2021

Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.

29-Nov-2021

GBM AGILE Opens to Paxalisib in Canada

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug.

15-Nov-2021

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Office

In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States.

11-Nov-2021

PNOC Study in Childhood Brain Cancer Enrols First Patient

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study.

08-Nov-2021

Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

Kazia Therapeutics Ltd's CEO Dr James Garner tells Proactive they've officially enrolled the first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. The phase one study will focus primarily on understanding the safety, tolerability and pharmacokinetics of EVT801 across a range of doses.

04-Nov-2021

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.

26-Oct-2021

Edison TV: Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

14-Sep-2021

Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

21-Jul-2021

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.

22-Apr-2021

Biotech Dispatch: Kazia licenses global rights to potential first-in-class oncology drug

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.